Kindstar, ACD Partner on RNA-based MDx | GenomeWeb

NEW YORK (GenomeWeb News) – Kindstar Global will validate and implement Advanced Cell Diagnostics' RNAscope technology-based molecular diagnostic assays as part of a partnership the firms announced today.

The firms said that the deal will allow Kindstar to leverage ACD's RNA biomarker analysis platform to offer new cancer diagnostic tests to the 3,300-plus hospitals in Kindstar's network in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.